Literature DB >> 6519123

Pharmacokinetics of [4-14C] mofebutazone after oral administration in man.

M A Kassem, K E Schulte.   

Abstract

The pharmacokinetics of mofebutazone was investigated in man after oral administration of [4-14C] mofebutazone in suspension form (7 mg/kg body weight). The blood concentration/time course was found to fit a two compartment open model with first order absorption (ka = 10.1 h-1) where elimination (kel = 0.304 h-1) occurs only from compartment 1. The maximum concentration was reached after 0.3 h in compartment 1 and after 2 h in compartment 2. Mofebutazone was found to be excreted almost exclusively via the kidney; 97% of the administered dose was found in urine already at 72 h. Excretion takes place very rapidly; 24% of the dose was excreted in 1.5 h and 45% in 3 h. 92% of the mofebutazone excreted was the conjugated form. Two glucuronides were detected in the 24 h urine; one of these seemed to be identical to a glucuronide fractionated from the urine of rat. The renal clearance of mofebutazone in man was found to be 3.38 l/h. The almost complete recovery of mofebutazone in the urine indicates that after oral administration, this drug has a very high bioavailability via the oral route.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6519123     DOI: 10.1007/BF03189645

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  7 in total

1.  [Toxicity and kinetics of the elimination of 4-butyl-2-phenyl-3, 5-pyrazolidinedione compared with that of the 1,2-diphenyl derivative].

Authors:  V SCARSELLI
Journal:  Farmaco Sci       Date:  1959

2.  [Studies on the effect of uremia on phenylbutazone and aminophenazone metabolism in man].

Authors:  H W Leber; A Harders; G Schütterle
Journal:  Klin Wochenschr       Date:  1972-12-01

3.  Comparison of phenyl- and monophenylbutazone (Mobutazon), especially in respect to the incidence of side effects. A double-blind study.

Authors:  S Thune
Journal:  Acta Rheumatol Scand       Date:  1967

4.  Disposition of [4-14C]mofebutazone in the rat.

Authors:  V M Bass; R I Mrongovius; K E Schulte
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

5.  The embryotoxic effect on rabbits of monophenylbutazone (monazan) compared with phenylbutazone and thalidomide.

Authors:  V Larsen; E Bredahl
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1966

6.  Metabolism of phenylbutazone in man.

Authors:  W Dieterle; J W Faigle; F Früh; H Mory; W Theoblad; K O Alt; W J Richter
Journal:  Arzneimittelforschung       Date:  1976-04

7.  Rheumatoid arthritis: comparison of treatment with monophenylbutazone and phenylbutazone.

Authors:  J F Woodbury; W A Turner; R Tiongson
Journal:  Can Med Assoc J       Date:  1969-12-27       Impact factor: 8.262

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.